Dror Bashan
Insider (Form 4 reporting owner): PRESIDENT AND CEO CIK 1781450Name as filed: Bashan DrorIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 11 Apr 2022, bought $294K in 3 open-market purchases of Protalix BioTherapeutics.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Protalix BioTherapeutics PLX | PRESIDENT AND CEO | 11 Apr 2022 | 19 Dec 2025 | 3$294K | – |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | too few trades3 trades | too few trades3 trades | too few trades2 trades |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2025 | 1 | $101K | – | – | $101K |
| 2023 | 1 | $90K | – | – | $90K |
| 2022 | 1 | $102K | – | – | $102K |
Every trade
3, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 19 Dec 2025 | Protalix BioTherapeutics PLX | Buy | 56,000 | $1.81 | $101K | No | Form 4filed 23 Dec 2025 |
| 19 Oct 2023 | Protalix BioTherapeutics PLX | Buy | 64,516 | $1.40 | $90K | No | Form 4filed 20 Oct 2023 |
| 11 Apr 2022 | Protalix BioTherapeutics PLX | Buy | 68,000 | $1.50 | $102K | Not stated | Form 4filed 13 Apr 2022 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.